Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok – stock.adobe.com
The Switzerland-based biopharmaceutical company Debiopharm Research & Manufacturing has announced a license agreement with Oncodesign Services, of Dijon, France, for the use of a technology known as AbYlink for preclinical services (1). In a press release on April 24, 2025, Debiopharm explained that AbYlink is a rapid, regio-selective bioconjugation technology designed for use in therapeutic and non-invasive diagnostic applications.
Under the terms of the agreement, Oncodesign will…
